Below are NHS England clinical commissioning policies for drugs which have been removed from the NHS Payment Scheme Annex A. Generic or biosimilar versions are available, meaning acquisition costs have significantly reduced over time, supporting removal from Annex A and into prices (tariffs). These drugs will not be reimbursed outside of prices.

Providers should ensure they have appropriate governance arrangements in place when considering the off-label use of medicines; access to these legacy policies has been maintained for providers to refer to if required to support their local decision-making and governance.

These policies have only been updated to reflect that the drugs are no longer considered high-cost and to remove the requirement for prior approval (Blueteq). They will not be updated further and Trusts should consider any future NICE guidance specific to the indication.

• Adalimumab for refractory chronic non-bacterial osteomyelitis/osteitis (CNO) (all ages)
• Everolimus for prevention of organ rejection following heart transplantation
• Infliximab (remicade) as anti-TNF alpha treatment option for paediatric patients with severe refractory uveitis
• Infliximab for progressive pulmonary sarcoidosis in adults
• Infliximab for the treatment of hidradenitis suppurativa
• Rituximab for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and vasculitis of the peripheral nervous system (adults)
• Rituximab for connective tissue disease associated with interstitial lung disease
• Rituximab for the treatment of primary Sjogren’s syndrome (PSS) in adults
• Rituximab for the treatment of refractory focal segmental glomerulosclerosis in the native kidney in adults
• Ustekinumab for refractory Crohn’s disease in pre-pubescent children